EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

被引：1

作者：

Powles, Thomas

van der Heijden, Michiel Simon

Loriot, Yohann

Bedke, Jens

Valderrama, Begona P.

Iyer, Gopa

Kikuchi, Eiji

Hoffman-Censits, Jeannie

Vulsteke, Christof

Drakaki, Alexandra

Rausch, Steffen

Arafat, Waddah

Park, Se Hoon

Swami, Umang

Li, Jian-Ri

Gorla, Seema Rao

Homet Moreno, Blanca

Yu, Xuesong

Lu, Yi-Tsung

Gupta, Shilpa

机构：

[1] Queen Mary Univ London, St Bartholomews Hosp, Barts Canc Inst, London, England

[2] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[3] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France

[4] Univ Paris Saclay, Dept Essais Precoces, Villejuif, France

[5] Klinikum Stuttgart, Dept Urol, Stuttgart, Germany

[6] Klinikum Stuttgart, Eva Mayr Stihl Canc Ctr, Stuttgart, Germany

[7] Hosp Univ Virgen del Rocio, Seville, Spain

[8] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, New York, NY USA

[9] St Marianna Univ, Dept Urol, Sch Med, Kawasaki, Kanagawa, Japan

[10] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[11] Maria Middelares Hosp, Dept Med Oncol, Antwerp, Belgium

[12] Univ Calif Los Angeles, Los Angeles, CA USA

[13] Eberhard Karls Univ Tubingen, Dept Urol, Tubingen, Germany

[14] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA

[15] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[16] Univ Utah, Dept Med, Huntsman Canc Inst, Salt Lake City, UT USA

[17] Taichung Vet Gen Hosp, Dept Surg, Div Urol, Taichung, Taiwan

[18] Astellas Pharma Inc, Northbrook, IL USA

[19] Merck & Co Inc, Rahway, NJ USA

[20] Pfizer Inc, Bothell, WA USA

[21] Cleveland Clin, Cleveland, OH USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.5_suppl.664

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[41] Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)
McGregor, B. A.
Sonpavde, G. P.
Kwak, L.
Gao, X.
Berg, S.
Mantia, C.
Wei, X. X.
Ravi, P.
Michaelson, M. D.
Choueiri, T. K.
Bellmunt, J.
ANNALS OF ONCOLOGY, 2024, 35 : S1153 - S1154
[42] Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.
Bamias, Aristotelis
Davis, Ian D.
Galsky, Matt D.
Arija, Jose Angel Arranz
Kikuchi, Eiji
Grande, Enrique
del Muro, Xavier Garcia
Park, Se Hoon
De Giorgi, Ugo
Alekseev, Boris
Mencinger, Marina
Izumi, Kouji
Puente, Javier
Li, Jian-Ri
Bene-Tchaleu, Fabiola
Mariathasan, Sanjeev
Lee, Chooi Peng
Bernhard, Sandrine
De Santis, Maria
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[43] Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress)
Powles, T.
Grande, E.
Van Der Heijden, M.
Necchi, A.
Iyer, G.
Drakaki, A.
Loriot, Y.
Sokolowski, K.
Zhang, W.
Galsky, M.
EUROPEAN UROLOGY, 2024, 85 : S1721 - S1721
[44] EV-301: A phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy.
Petrylak, Daniel
Rosenberg, Jonathan
Duran, Ignacio
Loriot, Yohann
Sonpavde, Guru
Wu, Chunzhang
Gartner, Elaina
Melhem-Bertrandt, Amal
Powles, Thomas
CLINICAL CANCER RESEARCH, 2020, 26 (15) : 59 - 60
[45] First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC)
Rosenberg, J. E.
Flaig, T. W.
Friedlander, T. W.
Milowsky, M. I.
Srinivas, S.
Petrylak, D. P.
Merchan, J. R.
Bilen, M. A.
Carret, A. -S.
Yuan, N.
Sasse, C.
Hoimes, C. J.
SWISS MEDICAL WEEKLY, 2020, : 26S - 27S
[46] Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130.
Davis, Ian D.
Galsky, Matthew D.
del Muro, Xavier Garcia
Park, Se Hoon
De Giorgi, Ugo
Alekseev, Boris
Mencinger, Marina
Izumi, Kouji
Puente, Javier
Li, Jian-Ri
Arranz, Jose Angel
Bamias, Aristotelis
Grande, Enrique
Kikuchi, Eiji
Mecke, Almut
Mariathasan, Sanjeev
Shen, Xiaodong
Huang, Hannah
De Santis, Maria
CANCER RESEARCH, 2021, 81 (13)
[47] Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Rosenberg, Jonathan E.
Powles, Thomas
Sonpavde, Guru P.
Loriot, Yohann
Duran, Ignacio
Lee, Jae-Lyun
Matsubara, Nobuaki
Vulsteke, Christof
Castellano, Daniel E.
Mamtani, Ronac
Wu, Chunzhang
Matsangou, Maria
Campbell, Mary S.
Petrylak, Daniel P.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[48] Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up
Gupta, Shilpa
Rosenberg, Jonathan E.
Mckay, Rana R.
Flaig, Thomas W.
Petrylak, Daniel P.
Hoimes, Christopher J.
Friedlander, Terence W.
Bilen, Mehmet Asim
Srinivas, Sandy
Burgess, Earle F.
Merchan, Jaime R.
Tagawa, Scott T.
Brown, Jason R.
Yu, Yao
Carret, Anne-Sophie
Wirtz, Heidi
Guseva, Maria
Moreno, Blanca Homet
Milowsky, Matthew I.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[49] Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).
Galsky, Matt D.
Grande, Enrique
Necchi, Andrea
Koontz, Michael Zach
Iyer, Gopa
Campbell, Matthew T.
Drakaki, Alexandra
Loriot, Yohann
Sokolowski, Kevin M.
Zhang, Wei
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS717 - TPS717
[50] EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
Rosenberg, J. E.
Powles, T.
Sonpavde, G. P.
Loriot, Y.
Duran, I.
Lee, J. -L.
Matsubara, N.
Vulsteke, C.
Castellano, D.
Mamtani, R.
Wu, C.
Matsangou, M.
Campbell, M.
Petrylak, D. P.
ANNALS OF ONCOLOGY, 2023, 34 (11) : 1047 - 1054

← 1 2 3 4 5 →